- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.07. | Moderna to lay of 10% of workforce in 'difficult but necessary step' | ||
| 31.07. | Lilly's Mounjaro protects heart health in large diabetic study | ||
| 30.07. | Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval | ||
| 30.07. | Vinay Prasad's ouster leaves biotech guessing at FDA direction | ||
| 30.07. | J&J tests direct CAR-T marketing with first Carvykti ad | ||
| 29.07. | Merck plans spending shift to boost business beyond Keytruda | ||
| 29.07. | Novo cuts guidance, names new CEO as obesity drug challenges mount | ||
| 29.07. | Bavarian Nordic agrees to $3B take-private deal | ||
| 29.07. | Bain leads $300M investment in startup built on Bristol Myers immune drugs | ||
| 29.07. | Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival | ||
| 28.07. | FDA allows Sarepta to resume some Elevidys shipments | ||
| 28.07. | Adaptimmune, seeking to stay afloat, sells off cell therapies | ||
| 28.07. | Celcuity shares triple on late-stage results for breast cancer therapy | ||
| 28.07. | Atai backs away from schizophrenia drug after trial failure | ||
| 28.07. | GSK pays $500M to enter drugmaking alliance with Hengrui | ||
| 28.07. | GenAI and real-world data in pharma: 4 questions to fuel effective insights | ||
| 28.07. | Redefining commercial success in specialty lite with alternative channels | ||
| 25.07. | FDA delays approval decision for Bayer menopause therapy | ||
| 25.07. | Bristol Myers shuffles its executive ranks with new CMO | ||
| 25.07. | In reversal, European regulators take positive view on Lilly Alzheimer's drug | ||
| 25.07. | Sarepta woes mount as Duchenne gene therapy knocked back in Europe | ||
| 24.07. | A TCG offshoot pulls in $400M for biotech startup creation | ||
| 24.07. | Galapagos, having backtracked on split, weighs sale of cell therapy business | ||
| 24.07. | Rocket lays off staff; Abivax capitalizes on immune drug data | ||
| 24.07. | [Podcast] The Progress Profile: Alzheimer's Research in Focus |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .